- Home
- CERO vs SBFM Comparison
CERO vs SBFM Comparison
Compare CERO & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- SBFM
- Stock Information
- Founded
- CERO 2017
- SBFM 2006
- Country
- CERO United States
- SBFM United States
- Employees
- CERO N/A
- SBFM N/A
- Industry
- CERO
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- SBFM Health Care
- Exchange
- CERO Nasdaq
- SBFM Nasdaq
- Market Cap
- CERO 6.1M
- SBFM 6.7M
- IPO Year
- CERO N/A
- SBFM N/A
- Fundamental
- Price
- CERO $5.39
- SBFM $1.67
- Analyst Decision
- CERO Strong Buy
- SBFM Strong Buy
- Analyst Count
- CERO 2
- SBFM 1
- Target Price
- CERO $45.00
- SBFM $15.00
- AVG Volume (30 Days)
- CERO 82.8K
- SBFM 62.2K
- Earning Date
- CERO 11-18-2025
- SBFM 11-04-2025
- Dividend Yield
- CERO N/A
- SBFM N/A
- EPS Growth
- CERO N/A
- SBFM N/A
- EPS
- CERO N/A
- SBFM N/A
- Revenue
- CERO N/A
- SBFM $36,341,741.00
- Revenue This Year
- CERO N/A
- SBFM $32.20
- Revenue Next Year
- CERO N/A
- SBFM $32.74
- P/E Ratio
- CERO N/A
- SBFM N/A
- Revenue Growth
- CERO N/A
- SBFM 19.22
- 52 Week Low
- CERO $4.27
- SBFM $1.17
- 52 Week High
- CERO $895.40
- SBFM $3.90
- Technical
- Relative Strength Index (RSI)
- CERO 40.84
- SBFM 67.82
- Support Level
- CERO $5.18
- SBFM $1.50
- Resistance Level
- CERO $5.45
- SBFM $1.67
- Average True Range (ATR)
- CERO 0.24
- SBFM 0.08
- MACD
- CERO 0.09
- SBFM 0.01
- Stochastic Oscillator
- CERO 56.96
- SBFM 73.44
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.